Abstract:Objective: To explore the influence of storage and delivery conditions of the peripheral blood samples from patients with chronic myeloid leukemia (CML) on the real-time quantitative PCR (RQ-PCR) detection of the BCR-ABL (P210) transcript levels. Methods: The peripheral blood samples of 84 CML patients were collected. The same sample was divided into different groups according to storage time (0, 6, 12, 24, 48, and 72 h) , temperature (room temperature, 18-24 ℃; low temperature, 2-8 ℃) , and vibration conditions (3, 6, and 12 h) . RQ-PCR was used to detect BCR-ABL (P210) transcript levels of the different groups. This study logarithmically transformed (log(10N)) the original data [BCR-ABL copy number, ABL copy number, and BCR-ABL (P210) transcript levels]. Results: ①Agarose gel electrophoresis showed significant RNA degradation of samples after storage for 48 and 72 h at room temperature. ②Among the overall samples, the BCR-ABL copy number of the samples stored at room temperature for 48 and 72 h was significantly lower than that of the samples stored at low temperature (P<0.05) . However, the BCR-ABL (P210) transcript levels had no significant difference between samples stored at low temperature and room temperature. ③No significant changes were noted in the BCR-ABL (P210) transcript levels at different storage times (6, 12, 24, 48, and 72 h) regardless of storage temperature (P>0.05) compared with that at baseline (0 h, -0.56±1.51) . ④ The BCR-ABL copy number of the overall sample only decreased significantly (P<0.05) at 48 h (2.93±1.59) and 72 h (2.79±1.42) compared with that at baseline (0 h, 3.35±1.60) when stored at room temperature. The ABL copy number in the overall sample decreased significantly at 48 and 72 h (whether low and room temperature; P<0.05) . However, no significant changes were noted in the BCR-ABL (P210) transcript levels after vibration for 3 h (-1.29±1.81) , 6 h (-1.24±1.72) , and 12 h (-1.18±1.68; P>0.05) compared with that at baseline (0 h, -0.60±1.37) . Conclusion: Sample storage time, storage temperature, and vibration can interfere with the results of BCR-ABL and ABL copy number but have no significant effect on the quantitative determination of BCR-ABL (P210) transcript levels. This study provides strong support for the feasibility of transregional transportation of peripheral blood samples from patients with CML.

THE DIFFERENCES AND CORRELATIONS OF BCR-ABL TRANSCRIPTS BETWEEN PERIPHERAL BLOOD AND BONE MARROW ASSAYS ARE ASSOCIATED WITH THE MOLECULAR RESPONSES IN THE BONE MARROW FOR CHRONIC MYELOGENOUS LEUKEMIA

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Outcome Prediction by the Transcript Level of BCR-ABL at 3 Months in Patients with Chronic Myeloid Leukemia Treated with Imatinib--a Single Institution Historical Experience.

[Comparison of Simultaneous Bone Marrow Cytogenetic and Peripheral Blood Molecular Responses in Chronic Myeloid Leukemia].

[Monitoring Bcr/abl Mrna Levels in Imatinib Mesylate Treated Chronic Myeloid Leukemia Patients by Real-Time Quantitative RT-PCR].

[Monitoring Bcr-Abl Mrna Levels by Real-Time Quantitative RT-PCR in Chronic Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

[Significance of Quantitative Detection of Bcr-Abl Mrna in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplant].

Different Kinetic Patterns of BCR‐ABL Transcript Levels in Imatinib‐treated Chronic Myeloid Leukemia Patients after Achieving Complete Cytogenetic Response

Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia

Which Method Better Evaluates the Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib Treatment, BCR-ABL(IS) or Log Reduction from the Baseline Level?

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].

[Comparative Study of Cytogenetic Response Evaluated by Conventional Banding Analysis and Fluorescence in Situ Hybridization in Chronic Myeloid Leukemia Patients During Tyrosine Kinase Inhibitor Treatment].

Real-time Reverse-Transcriptase Polymerase Chain Reaction in Monitoring BCR/ABL Transcript Levels in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cells Transplantation

Expression and significance of BCR-ABL mRNA in chronic myeloid leukemia patients by qPCR

Application of real-time quantification polymerase chain reaction in detecting the expression of BCR-ABL in chronic myelogenous leukemia cells

[The Influence of Peripheral Blood Sample Storage and Delivery on the Quantitative Detection Result of BCR-ABL (P210) Transcript Levels].

A multicenter comparison study on the quantitative detection of bcr-abl (P210) transcript levels in China]

Association between the BCR-ABL gene transcripts and the laboratory hematological profile

The Significance of Serial Monitoring of Bcr-Abl Transcripts Levels after Allogeneic Hematopoietic Stem Cell Transplantation in Screening Chronic Myeloid Leukemia Patients with Low Relapse

Correlation Between Imatinib Trough Concentration and Efficacy in Chinese Chronic Myelocytic Leukemia Patients